Skip to content
Get started

Your research digest, every morning

Each morning ReadSearch reads the new papers in the fields you follow and brings you the few worth your time, ranked for you and explained in plain language.

Get started See a sample digest

Every account starts with 30 days of Researcher. Nothing is charged until day 30.

Today’s digest

Monday 9 November

5 papers · about 8 min for the sample reader, a cardiologist

Your fields

  1. Semaglutide and cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease without diabetesPaper of the day · 96 field fit
  2. Continuous glucose monitoring in non-diabetic heart failure: a pilot cohort91 field fit

Your methods

  1. External validation of a transformer triage model across four health systems88 technique fit
  2. Wearable-derived atrial fibrillation burden and stroke risk80 technique fit

Other fields

  1. Federated learning across hospitals without sharing records: a benchmark on readmission prediction76 cross-field fit
ReadSearchPlate 1 · Title1 / 8

Paper briefing · Cardiology

A weight‑loss drug that also protects the heart

Semaglutide and cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease without diabetes

Lindholm A, Okonkwo C, Varga M and Reyes‑Ortiz J

Source

The Lancet

Field

Cardiology

Reading

3 min

iContents

  1. 02Aboutpl. 2
  2. 03Problem and solutionpl. 3
  3. 04Resultspl. 4
  4. 05Results in numberspl. 5
  5. 06Results comparedpl. 6
  6. 07Use cases in your fieldpl. 7
  7. 08Methods and next stepspl. 8
Lindholm A et al. · The LancetAI-written summary
ReadSearchTitle1 / 8

Paper briefing · Cardiology

A weight‑loss drug that also protects the heart

Semaglutide and cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease without diabetes

Lindholm A, Okonkwo C, Varga M and Reyes‑Ortiz J

Source

The Lancet

Field

Cardiology

Reading

3 min

iContents

  1. 02Aboutpl. 2
  2. 03Problem and solutionpl. 3
  3. 04Resultspl. 4
  4. 05Results in numberspl. 5
  5. 06Results comparedpl. 6
  6. 07Use cases in your fieldpl. 7
  7. 08Methods and next stepspl. 8
Lindholm A et al.AI summary
ReadSearchPlate 2 · About2 / 8

About this paper

aThe question

Semaglutide is widely used for diabetes and obesity. Whether it also prevents heart attacks and strokes in people without diabetes has been an open question for cardiologists.

bWhat this paper adds

This trial randomised adults with overweight or obesity and established cardiovascular disease, none with diabetes, to weekly semaglutide or placebo, and followed them for major cardiovascular events.

Lindholm A et al. · The LancetAI-written summary
ReadSearchAbout2 / 8

About this paper

aThe question

Semaglutide is widely used for diabetes and obesity. Whether it also prevents heart attacks and strokes in people without diabetes has been an open question for cardiologists.

bWhat this paper adds

This trial randomised adults with overweight or obesity and established cardiovascular disease, none with diabetes, to weekly semaglutide or placebo, and followed them for major cardiovascular events.

Lindholm A et al.AI summary
ReadSearchPlate 3 · Problem and solution3 / 8

Problem and solutionread left to right

aThe problem

Most cardiovascular outcome trials of GLP‑1 drugs enrolled people with type 2 diabetes. For the much larger group with overweight or obesity and established heart disease but no diabetes, the evidence was indirect.

bProposed solution

A placebo‑controlled outcomes trial

Hypothesis

Lowering weight and inflammation with semaglutide will reduce cardiovascular events even without diabetes.

cWhy it should work

Earlier diabetes trials showed fewer events than glucose lowering alone would explain, which pointed to effects beyond blood sugar: on weight, blood pressure and inflammation.

Lindholm A et al. · The LancetAI-written summary
ReadSearchProblem · solution3 / 8

Problem and solutionread left to right

aThe problem

Most cardiovascular outcome trials of GLP‑1 drugs enrolled people with type 2 diabetes. For the much larger group with overweight or obesity and established heart disease but no diabetes, the evidence was indirect.

bProposed solution

A placebo‑controlled outcomes trial

Hypothesis

Lowering weight and inflammation with semaglutide will reduce cardiovascular events even without diabetes.

cWhy it should work

Earlier diabetes trials showed fewer events than glucose lowering alone would explain, which pointed to effects beyond blood sugar: on weight, blood pressure and inflammation.

Lindholm A et al.AI summary
ReadSearchPlate 4 · Results4 / 8

Results

aFinding

Major cardiovascular events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group.

→ Drawn to scale on plate 6

The benefit appeared early, before most of the weight loss, which suggests effects beyond weight alone. More people stopped the drug because of side effects.

bFrom the paper

“Over a mean follow‑up of 3.3 years, a primary outcome event occurred in 6.5% of patients in the semaglutide group and in 8.0% of those in the placebo group, a relative reduction of 20%.”

Word for word
from the abstract

Lindholm A et al. · The LancetAI-written summary
ReadSearchResults4 / 8

Results

aFinding

Major cardiovascular events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group.

→ Drawn to scale on plate 6

The benefit appeared early, before most of the weight loss, which suggests effects beyond weight alone. More people stopped the drug because of side effects.

bFrom the paper

“Over a mean follow‑up of 3.3 years, a primary outcome event occurred in 6.5% of patients in the semaglutide group and in 8.0% of those in the placebo group, a relative reduction of 20%.”

Word for word
from the abstract

Lindholm A et al.AI summary
ReadSearchPlate 5 · Results in numbers5 / 8

Results in numberseach on its own scale

aFewer major

20%

Fewer major events

Semaglutide lowered the risk of a major cardiovascular event by 20% relative to placebo.

bWeight change

−9.4%

Weight change

Mean body weight changed by −9.4% with semaglutide, against −0.9% with placebo.

cFollow‑up

3.3 yrs

Follow‑up

Participants were followed for a mean of 3.3 years.

dStopped

16.6%

Stopped for side effects

16.6% stopped the drug because of side effects, mostly gastrointestinal, against 8.2% on placebo.

Lindholm A et al. · The LancetAI-written summary
ReadSearchIn numbers5 / 8

Results in numberseach on its own scale

aFewer major events

20%

Semaglutide lowered the risk of a major cardiovascular event by 20% relative to placebo.

bWeight change

−9.4%

Mean body weight changed by −9.4% with semaglutide, against −0.9% with placebo.

cFollow‑up

3.3 yrs

Participants were followed for a mean of 3.3 years.

dStopped for side effects

16.6%

16.6% stopped the drug because of side effects, mostly gastrointestinal, against 8.2% on placebo.

Lindholm A et al.AI summary
ReadSearchPlate 6 · Results compared6 / 8

Results compareddrawn to scale, from zero

aFigure

bLegend

  • Semaglutide
  • Placebo

Fig. 6 | % with a major event

Scale
linear, from 0
Lindholm A et al. · The LancetAI-written summary
ReadSearchCompared6 / 8

Results compareddrawn to scale, from zero

aFigure

bLegend

  • Semaglutide
  • Placebo

Fig. 6 | % with a major event

Scale
linear, from 0
Lindholm A et al.AI summary
ReadSearchPlate 7 · Use cases in your field7 / 8

For a cardiologist, this moves semaglutide from a weight drug to a prevention option.

aIn Cardiology

  1. a1

    Who might qualify

    Patients like those in the trial: established disease, a BMI of 27 or more, no diabetes.

  2. a2

    What to watch

    Gastrointestinal side effects drove most discontinuations, so follow‑up in the first months matters.

  3. a3

    Open questions

    Whether the benefit holds at lower doses, and how it compares with other risk‑lowering drugs.

bData point

1 in 67

67 dots · 1 filled

Patients treated over about three years for one fewer major event, from the absolute difference of 1.5 points.

Lindholm A et al. · The LancetAI-written summary
ReadSearchUse cases7 / 8

For a cardiologist, this moves semaglutide from a weight drug to a prevention option.

aIn Cardiology

  1. a1

    Who might qualify

    Patients like those in the trial: established disease, a BMI of 27 or more, no diabetes.

  2. a2

    What to watch

    Gastrointestinal side effects drove most discontinuations, so follow‑up in the first months matters.

  3. a3

    Open questions

    Whether the benefit holds at lower doses, and how it compares with other risk‑lowering drugs.

bData point

1 in 67

67 dots · 1 filled

Patients treated over about three years for one fewer major event, from the absolute difference of 1.5 points.

Lindholm A et al.AI summary
ReadSearchPlate 8 · Methods and next steps8 / 8

Methods and next steps

aMethod

Randomised, double‑blind, event‑driven

Neither participants nor investigators knew who received the drug, and the trial ran until a pre‑set number of primary events had accrued, so its size was fixed by events rather than by time.

bNext steps

  1. 1

    Read the methods and supplement

    Check the population, the adjudication of events and the subgroup results.

  2. 2

    Compare with the diabetes trials

    Set this result beside the earlier GLP‑1 outcome trials to see what is new.

  3. 3

    Check the guideline response

    Look for how cardiology societies have incorporated it.

Lindholm A et al. · The LancetAI-written summary
ReadSearchMethods · next8 / 8

Methods and next steps

aMethod

Randomised, double‑blind, event‑driven

Neither participants nor investigators knew who received the drug, and the trial ran until a pre‑set number of primary events had accrued, so its size was fixed by events rather than by time.

bNext steps

  1. 1

    Read the methods and supplement

    Check the population, the adjudication of events and the subgroup results.

  2. 2

    Compare with the diabetes trials

    Set this result beside the earlier GLP‑1 outcome trials to see what is new.

  3. 3

    Check the guideline response

    Look for how cardiology societies have incorporated it.

Lindholm A et al.AI summary
A sample day: the sample reader’s five papers in the digest’s three sections, and the Paper of the day as its slides. The papers are samples.

New papers every day from

  • PubMed
  • arXiv
  • bioRxiv
  • medRxiv
  • OpenAlex
How it works

Explained plainly

From the abstract to what it means

The same paper, as its authors wrote it, and as your digest gives it to you. A sample paper.

The abstract

201 words · 12 abbreviations and symbols

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events (MACE) in type 2 diabetes (T2D); whether semaglutide confers cardiovascular benefit in patients with established atherosclerotic cardiovascular disease (ASCVD) and overweight or obesity in the absence of diabetes has not been established. Methods: In this multicentre, double-blind, randomised, placebo-controlled, event-driven superiority trial, patients aged ≥45 years with prior myocardial infarction (MI), stroke or symptomatic peripheral artery disease (PAD) and a body-mass index (BMI) ≥27 kg/m², without diabetes, were assigned 1:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo. The primary endpoint was a composite of cardiovascular death, non-fatal MI or non-fatal stroke, analysed as time to first event. Results: Over a mean follow-up of 3.3 years, the primary endpoint occurred in 6.5% of the semaglutide group and 8.0% of the placebo group (hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.72–0.90; P<0.001). Mean change in body weight was −9.4% versus −0.9%. Adverse events leading to permanent discontinuation occurred in 16.6% versus 8.2%, predominantly gastrointestinal. Conclusions: In patients with pre-existing cardiovascular disease and overweight or obesity without diabetes, weekly semaglutide 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, non-fatal MI or non-fatal stroke.

Read the whole abstractShow less of the abstract

Your digest

96 words · no abbreviations

In shortIn people with heart disease and obesity but no diabetes, a weekly weight-loss drug cut heart attacks, strokes and heart deaths by a fifth.

The question
Earlier trials of these drugs only enrolled people with diabetes. Would the heart benefit hold without it?
What they did
Adults with past heart disease who were overweight took the drug or a dummy injection every week for about three years.
What they found
6.5% had a major heart event on the drug, 8.0% on placebo. The benefit came early, before most of the weight loss.
The catch
Twice as many stopped the drug for side effects, mostly stomach trouble.

Machine-written, marked as such, with a link to the paper to check anything you rely on.

Today’s papers

Real papers, as your dashboard shows them

Picked today by ReadSearch’s digest for four interests. These are real papers: open any of them at its source, no account needed. Sign up and the digest is built around your own field.

Get started
Machine LearningComputer Science & AICardiologyMedicine & HealthQuantum PhysicsPhysics & AstronomyAstrophysics of GalaxiesPhysics & Astronomy

RS Universe

See how your field connects to the rest of research

RS Universe is a 3D map of 31 million papers published from 2024 to 2026. Each point of light is a paper: papers sit with their topic, topics with their field, and fields that cite each other often sit close together.

Papers in the map
31,491,364
Fields and topics
26 and 4,516
Citations between them
159 million
Explore it in your trial See how it works

In both plans, from the first of your 30 days: Researcher opens as many maps as you like, Pro one a week.

RS Universe zoomed out to its whole map: 26 clusters of coloured points, one per field, on an ivory ground.RS Universe zoomed out to its whole map: 26 clusters of coloured points of light, one per field, on a dark night sky.
Recorded from RS Universe itself. Each colour is a field, and the map names every one. Zoomed out this far it draws a sample of the papers; more appear as you zoom in.

  • Explore a topic

    Type a subject and see how it divides into sub-themes, where to start reading and its links to other fields.

  • Open any paper

    The papers most like it, the ones it is linked to by citations, and Where fields meet: its links into other fields.

  • My neighbourhood

    Your saved papers marked in the map, the papers around them, and the nearby groups that hold none of them yet.

Keep up with your field without reading all of it

New papers appear faster than anyone can read them. ReadSearch reads them for you, every day, and keeps the few that matter to your work.

The daily digest

One morning read, built around your work

From choosing what it reads to the papers it brings you, in one place.

A daily digest, ranked for you

  • Every morning, the day’s new papers in your fields, scored and put in order: up to 5, not a hundred.
  • The day’s first paper is the Paper of the day, highlighted at the top of its section.
  • Ranked against your field, the interests you follow and the methods you ask for. Mark a paper not relevant and it leaves your digest.
See a sample digest

Your fields

Papers in the fields you follow.2 papers

Your methods

Papers that use the methods you work with.2 papers

96 out of 100
Field fit

Paper of the day

Choose exactly what it reads

  • One field from 113 and three or more of 246 interests, from machine learning and econometrics to cardiology and astrophysics.
  • Mark methods as preferred to rank papers that use them higher, or required to see only those. Change any of it, any day.
Get started

Settings, as the sample reader sees them: the interests they follow, chosen from the catalogue's areas, and three methods, one of them switched from Off to Preferred to Required.

Every paper, explained plainly

  • Each paper opens as a short set of slides: what it is about, the problem, what was found, the results in numbers, and what it could mean in your field.
  • Written for how you read and marked as machine-written, with a link to the source to check anything you rely on.
  • Four slide styles to choose from. Pick one on any paper or in Settings, and it is saved to your account.
Open a sample paper
ReadSearchPlate 5 · Results in numbers5 / 8

Results in numberseach on its own scale

aFewer major

20%

Fewer major events

Semaglutide lowered the risk of a major cardiovascular event by 20% relative to placebo.

bWeight change

−9.4%

Weight change

Mean body weight changed by −9.4% with semaglutide, against −0.9% with placebo.

cFollow‑up

3.3 yrs

Follow‑up

Participants were followed for a mean of 3.3 years.

dStopped

16.6%

Stopped for side effects

16.6% stopped the drug because of side effects, mostly gastrointestinal, against 8.2% on placebo.

Lindholm A et al. · The LancetAI-written summary
ReadSearchIn numbers5 / 8

Results in numberseach on its own scale

aFewer major events

20%

Semaglutide lowered the risk of a major cardiovascular event by 20% relative to placebo.

bWeight change

−9.4%

Mean body weight changed by −9.4% with semaglutide, against −0.9% with placebo.

cFollow‑up

3.3 yrs

Participants were followed for a mean of 3.3 years.

dStopped for side effects

16.6%

16.6% stopped the drug because of side effects, mostly gastrointestinal, against 8.2% on placebo.

Lindholm A et al.AI summary

Lettered panels and diagrams, like a figure in a journal.

See your reading

  • What you have read, day by day for the last two weeks, and in all.
  • Goals, streaks and badges only if you turn them on. They stay off until you do.
Open a sample profile
Papers read, all time
486
Days you read a digest
112
Days this week
1 of 7
Papers today
6
The last 14 days11 days with reading
  1. Tuesday 27 October: 3 to 5 papers
  2. Wednesday 28 October: 6 or more papers
  3. Thursday 29 October: No papers
  4. Friday 30 October: No papers
  5. Saturday 31 October: 6 or more papers
  6. Sunday 1 November: 3 to 5 papers
  7. Monday 2 November: 6 or more papers
  8. Tuesday 3 November: 3 to 5 papers
  9. Wednesday 4 November: No papers
  10. Thursday 5 November: 6 or more papers
  11. Friday 6 November: 6 or more papers
  12. Saturday 7 November: 3 to 5 papers
  13. Sunday 8 November: 6 or more papers
  14. Monday 9 November: 6 or more papers
The sample reader’s profile. Every paper opened counts, whether from the digest, a search or the library.

How it works

  1. Tell it what you work on

    Your role, one of 113 fields, three or more of 246 interests, and any methods you care about.

  2. It reads the day’s papers

    New work from 5 sources is scored against what you chose. A paper found in several places counts once.

  3. You read the few that matter

    Each morning, a ranked handful, each explained in plain language, with a link to the source.

How it’s different

There are many research tools. This is what ReadSearch is built around.

  • Every discipline

    113 fields in 5 areas, from clinical medicine to the humanities. Not only biomedicine, not only AI.

  • Ranked, not just filtered

    Papers are scored against the field, interests and methods you chose, then put in order.

  • Honest about AI

    Machine-written text is marked as such, and every paper links to its source.

Who it’s for

Written for the way you read

Tell ReadSearch who you are, and each paper’s breakdown is written for you.

ResearchersKeep up with a field that publishes faster than anyone can read.CliniciansThe trials and reviews that could change practice, without the backlog.StudentsLearn a field by reading its newest work, explained from the ground up.

The same sample paper, for a clinician

Semaglutide and cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease without diabetes

For a cardiologist, this moves semaglutide from a weight drug to a prevention option.

  • Who might qualify

    Patients like those in the trial: established disease, a BMI of 27 or more, no diabetes.

  • What to watch

    Gastrointestinal side effects drove most discontinuations, so follow-up in the first months matters.

  • The limits

    One trial at one dose: weigh it before changing care, and look for how the guidelines respond.

Each breakdown for a clinician covers evidence appraisal, patient-relevant outcomes and the limits of translation to care.

Interests clinicians follow, for example: Cardiology, Oncology, Infectious Disease and Neurology.

Get started

Pricing

Two plans, and 30 days to try everything

Every account starts with 30 days of Researcher, the full plan. You choose Pro or Researcher when you start and add a card. Nothing is charged until day 30, and not at all if you cancel before then.

At a partner university or company? Sign up with your work email and your institution’s 30% partner discount applies automatically.

Not ready to pay? Stay on Free: a digest of 5 papers each week with its audio briefing, 5 searches a day and your library. No card needed.

Cancel any time in Settings › Plan. If your plan ends, you’re on Free and your library and projects are kept. See the terms

For keeping up

Pro

$6.99 a month

or $5.59/mo billed yearly ($67.08). Save 20%

  • Your daily digest, with audio, and each paper broken down for your role
  • All the AI tools: Ask ReadSearch, your own PDFs, comparisons, citations, screening and reviews
  • Your library, history, search and import
  • Up to 5 followed topics, and 1 RS Universe map a week
Start your 30-day trial

Most complete

Researcher

$9.99 a month

or $7.99/mo billed yearly ($95.88). Save 20%

  • Everything in Pro
  • Unlimited topics and RS Universe maps
  • Filtering by technique, and following other fields
  • Why each RS Universe link is there
  • Exports of your library, groups, projects, screening and reviews
  • Early access to new features
Start your 30-day trial

Renews automatically until you cancel. Compare the plans in full

Questions

Where do the papers come from?

Every day from PubMed, arXiv, bioRxiv, medRxiv and OpenAlex, which indexes journals across every discipline. A paper found in several places is shown once.

Which fields does it cover?

113 research fields in 5 areas: clinical medicine, health and life sciences, computing and mathematics, engineering and physical sciences, and the social sciences and humanities.

How is my digest chosen?

The day’s papers are scored against the field and interests you set and the methods you mark as required or preferred. The best of them, in order, are your digest. Mark a paper not relevant and it leaves your digest.

Are the summaries written by AI?

Yes. A language model writes each paper’s plain-language breakdown from the paper itself, and the app marks that text as machine-written. Every paper links to its source.

Is there a free plan?

Yes. Without a paid plan you’re on Free: a digest of 5 papers each week with its audio briefing, 5 searches a day, one RS Universe map a week, and your library. The AI tools are in Pro and Researcher, and every account can try them with 30 days of Researcher, the full plan. Pro is $6.99 a month, or $5.59 a month billed yearly ($67.08); Researcher is $9.99 a month, or $7.99 a month billed yearly ($95.88). You choose one when you start the trial and add a card; it is charged on day 30 unless you cancel, then renews automatically until you cancel. There is no student discount, but readers at partner universities and companies get 30% off automatically.

What happens if I cancel?

Cancel any time in Settings › Plan. During the trial nothing is charged, and you keep everything until day 30. After that, you keep your plan to the end of the time you’ve paid for. Then you’re on Free: nothing is deleted, your library, projects and settings are kept, and choosing a plan again opens everything as you left it. You can download a copy of your data or delete your account at any time.

Read less, know more. Start with tomorrow’s papers.

Start your 30-day trial See today’s papers